Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (NASDAQ:DXCM) appointed Rick Osterloh to its Board of Directors, effective February 26, 2026. Osterloh brings more than 20 years of technology leadership and currently serves as Senior Vice President, Platforms & Devices at Google, overseeing Android, Pixel, Nest and Fitbit.
This appointment adds product, platform and AI-integrated hardware expertise to the Board to support Dexcom’s long-term product strategy and innovation in glucose biosensing.
Dexcom (NASDAQ:DXCM) will present an update at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026.
The live presentation begins at approximately 1:05 PM EST and will be concurrently webcast; archived video and webcast links will be available at investors.dexcom.com.
Dexcom (Nasdaq: DXCM) reported Q4 2025 revenue of $1.260 billion, up 13% year-over-year, and full-year 2025 revenue of $4.662 billion, up 16%.
GAAP operating income rose to $323.0 million (25.6% margin) in Q4; cash and marketable securities totaled $2.00 billion. Company launched the G7 15 Day CGM, received FDA clearance for Smart Basal, and reiterated 2026 revenue guidance of $5.16–$5.25 billion.
Dexcom (Nasdaq: DXCM) will roll out AI-enhanced Smart Food Logging and a redesigned Daily Insights in the Stelo app nationwide in the coming weeks. The update adds a nutrition database of over 1 million food items, multiple logging methods (text, barcode, photo), and personalized, card-based recommendations to help users track glucose, nutrition, activity, and sleep.
The company says these features build on prior Smart Food Logging and aim to reduce friction in meal tracking while providing evolving, AI-driven coaching; a reimagined Stelo app is planned later this year pending final development and approvals.
Dexcom (NASDAQ:DXCM) will release its fourth quarter and fiscal year 2025 results after market close on Thursday, February 12, 2026. Management will host a conference call and concurrent webcast to review Q4 and FY2025 performance starting at 4:30 p.m. Eastern Time the same day. The webcast link will be available and archived on the company investor relations site at investors.dexcom.com. To join the call by phone, dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and enter confirmation ID 9430114 about five minutes before the start time.
Dexcom (Nasdaq: DXCM) reported preliminary, unaudited Q4 2025 revenue of approximately $1.260 billion, up 13% year-over-year, with U.S. revenue of about $892 million (+11%) and international revenue of about $368 million (+18%). For fiscal 2025, preliminary revenue was approximately $4.662 billion, up 16% year-over-year. The company reiterated 2025 non-GAAP gross profit margin of ~61% and non-GAAP operating margin of 20–21%. For 2026, Dexcom anticipates revenue of $5.16–$5.25 billion (≈11–13% growth) with non-GAAP gross margin of 63–64% and operating margin of 22–23%. Dexcom also noted the initial launch of its G7 15 Day system and continued rollout of Stelo. Audited results and a conference call are scheduled for Feb 12, 2026 at 4:30 p.m. ET.
Dexcom (NASDAQ:DXCM) announced Jake Leach as president and CEO effective Jan. 1, 2026, and outlined 2026 priorities including a reimagined Stelo app with AI-powered personalization and enhanced food logging, expanded integrations, and the pharmacy launch of the Dexcom G7 15 Day continuous glucose monitor, which began shipping to pharmacies in early January 2026. Leach will speak at CES 2026 on Jan. 7 and present at the J.P. Morgan Healthcare Conference on Jan. 12. The release notes prior leadership grew revenue from about $250M to over $4.6B annually under the prior CEO.
Dexcom (NASDAQ:DXCM) launched Dexcom Academy, a personalised learning platform for healthcare professionals to strengthen confidence in continuous glucose monitoring (CGM) and support consistent diabetes care.
The platform is available as a desktop and mobile app in Belgium, Germany, Kingdom of Saudi Arabia, the Netherlands, and Spain, with further EMEA launches planned for 2026. Features include bite-sized modules, certification courses, case-study clinical scenarios, and training on Dexcom G7 and Dexcom ONE+. A 2025 Dexcom survey found 38% of HCPs in surveyed EMEA markets said ongoing education on diabetes technology could help address care challenges.
Dexcom (NASDAQ:DXCM) will launch the Dexcom G7 15 Day continuous glucose monitoring system in the U.S. on Dec. 1, 2025 for people 18 and older, initially through durable medical equipment (DME) providers with full retail availability to follow.
The system offers an industry-leading 15.5 days of sensor wear, an overall MARD of 8.0% for accuracy, Medicare coverage and meets therapeutic CGM category requirements. A study showed 73.9% of sensors lasted the full 15 days while ~26% may not. G7 15 Day connects with select automated insulin delivery systems and adds app features like Apple Watch connectivity, automated activity and medication logging, and a 12-hour replacement grace period.
Dexcom (NASDAQ: DXCM) announced on November 19, 2025 that the FDA cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer for adults 18+ with Type 2 diabetes using glargine U-100 long-acting insulin.
Dexcom Smart Basal uses Dexcom G7 15 Day sensor data plus logged doses to deliver personalized daily dose recommendations and reminders in the G7 15 Day app, and connects with Dexcom Clarity for provider prescribing and configuration. Availability in the US will follow the product launch; international rollout is being explored.